Trypsin inhibitory capacity in vernal keratoconjunctivitis

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 1, 2007, Pages 264-269

  Ghavami, Saeid ^a,c   Hashemi, Mohammad ^a,b   De Serres, Fredrick J ^d   Bajestani, Saeed Naghibzadeh ^e   Mehrabifar, Hamid ^b   Leonardi, Andrea ^f,g  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF MANITOBA   (Canada)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f UNIVERSITY OF PADOVA   (Italy)

^g Ophthalmology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ENZYME PRECURSOR; GELATINASE B; INTERSTITIAL COLLAGENASE; TRYPSIN INHIBITOR; SERINE PROTEINASE INHIBITOR; TRYPSIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VITRO STUDY; LACRIMAL FLUID; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SPECTROPHOTOMETRY; VERNAL CONJUNCTIVITIS; ALLERGIC CONJUNCTIVITIS; BLOOD; CHILD; ENZYMOLOGY; METABOLISM;

ADOLESCENT; ADULT; ALPHA 1-ANTITRYPSIN; CHILD; CONJUNCTIVITIS, ALLERGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; SERINE PROTEINASE INHIBITORS; TEARS; TRYPSIN;

EID: 33846895513     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0758     Document Type: Article

References (52)

1. Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Ret Eye Res. 2002;21:319-339.
2. Leonardi A, Brun P, Sartori MT, et al. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2005;46:1364-1370.
3. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
4. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler. 1995;376:345-355.
5. Ohno I, Ohtani H, Nitta Y, et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol. 1997;16:212-219.
6. Leonardi A, Brun P, Abatangelo G, Plebani M, Secchi AG. Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2003;44:3052-3058.
7. Abu El-Asrar AM, Van Aelst I, Al-Mansouri S, et al. Gelatinase B in vernal keratoconjunctivitis. Arch Ophthalmol. 2001;119:1505-1511.
8. de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003;64:382-397.
9. Ghavami S, Hashemi M, Shahriari HA, et al. Alpha-1-antitrypsin phenotypes and HLA-B27 typing in uveitis patients in southeast Iran. Clin Biochem. 2005;38:425-432.
10. Hashemi M, Alavian SM, Ghavami S, et al. High prevalence of alpha 1 antitrypsin phenotypes in viral hepatitis B infected patients in Iran. Hepatol Res. 2005;33:292-297.
11. Montanelli A, Mainardi E, Pini L, Corda L, Grassi V. Alpha-1-antitrypsin deficiency and nephropathy. Nephron. 2002;90:114-115.
12. Stockley RA. Alpha-1-antitrypsin deficiency: what next? Thorax. 2000;55:614-618.
13. Vila N, Millan M, Ferrer X, Riutort N, Escudero D. Levels of alpha1-antitrypsin in plasma and risk of spontaneous cervical artery dissections: a case-control study. Stroke. 2003;34:E168-E169.
14. Mast AE, Enghild JJ, Nagase H, et al. Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin). J Biol Chem. 1991;266:15810-15816.
15. Breit SN, Penny R. The role of alpha 1 protease inhibitor (alpha 1 antitrypsin) in the regulation of immunologic and inflammatory reactions. Aust NZ J Med. 1980;10:449-453.
16. Breit SN, Robinson JP, Penny R. The effect of alpha 1 antitrypsin on phagocyte function. J Clin Lab Immunol. 1983;10:147-149.
17. Carrell RW. alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage. J Clin Invest. 1986;78:1427-1431.
18. Curiel DT, Vogelmeier C, Hubbard, RC Stier LE, Crystal RG. Molecular basis of alpha 1-antitrypsin deficiency and emphysema associated with the alpha 1-antitrypsin mineral springs allele. Mol Cell Biol. 1990;10:47-56.
19. Ebihara N, Funaki T, Takai S, et al. Tear chymase in vernal keratoconjunctivitis. Curr Eye Res. 2004;28:417-420.
20. Ebihara N, Takai S, Miyazaki M, Murakami A. Mast cell chymase induces conjunctival epithelial cell apoptosis by a mechanism involving degradation of fibronectin. Curr Eye Res. 2005;30:429-435.
21. Fukagawa K, Saito H, Azuma N, et al. Histamine and tryptase levels in allergic conjunctivitis and vernal keratoconjunctivitis. Cornea. 1994;13:345-348.
22. Irani AM, Butrus SI, Tabbara KF, Schwartz LB. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol. 1990;86:34-40.
23. Margrini L, Bonini S, Centofanti M, Schiavone M, Bonini S. Tear tryptase levels and allergic conjunctivitis. Allergy. 1996;51:577-581.
24. Maruyama I, Zhou L, Sugar J, Yue BY. Normal expression levels of cathepsins, protease inhibitors, and Sp1 in conjunctival tissues from patients with keratoconus. Curr Eye Res. 2000;21:886-890.
25. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983;52:655-709.
26. Potempa J, Korzus E, Travis J. The serpin superfamify of proteinase inhibitors: structure, function, and regulation. J Biol Chem. 1994;269:15957-15960.
27. Loebermann H, Tokuoka R, Deisenhofer J, Huber R. Human alpha 1-proteinase inhibitor: crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984;177:531-557.
28. Morii M, Travis J. Amino acid sequence at the reactive site of human alpha 1-antichymotrypsin. J Biol Chem. 1983;258:12749-12752.
29. Knauper V, Reinke H, Tschesche H. Inactivation of human plasma alpha 1-proteinase inhibitor by human PMN leucocyte collagenase. FEBS Lett. 1990;263:355-357.
30. Trocme SD, Leiferman KM, George T, et al. Neutrophil and eosinophil participation in atopic and vernal keratoconjunctivitis. Curr Eye Res. 2003;26:319-325.
31. Perlmutter DH. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest. 2002;110:1579-1583.
32. Carrell RW, LomasDA. Conformational disease. Lancet. 1997;350:134-138.
33. Engstrom G, Stavenow L, Hedblad B, et al. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes. 2003;52:442-447.
34. Gupta AK, Sarin GS, Mathur MD, Ghosh B. Alpha 1-antitrypsin and serum albumin in tear fluids in acute adenovirus conjunctivitis. Br J Ophthalmol. 1988;72:390-393.
35. Prause JU. Serum albumin, serum antiproteases and polymorphonuclear leucocyte neutral collagenolytic protease in the tear fluid of normal healthy persons. Acta Ophthalmol (Copenh). 1983;61:261-271.
36. Leonardi A, Borghesan F, Faggian D, et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol. 2000;129:151-158.
37. Trocme SD; Aldave SJ. The eye and the eosinophil. Surv Ophthalmol. 1994;39:241-252.
38. Matheson NR, Travis J. Differential effects of oxidizing agents on human plasma alpha 1-proteinase inhibitor and human neutrophil myeloperoxidase. Biochemistry. 1985;24:1941-1945.
39. Carp H, Janoff A. Potential mediator of inflammation: phagocyte-derived oxidants suppress the elastase-inhibitory capacity of alpha 1-proteinase inhibitor in vitro. J Clin Invest. 1980;66:987-995.
40. Vogt W. Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic Biol Med. 1995;18:93-105.
41. Maier KL, Leuschel L, Costabel U. Increased oxidized methionine residues in BAL fluid proteins in acute or chronic bronchitis. Eur Respir J. 1992;5:651-658.
42. Pereira PJ, Bergner A, Macedo-Ribeiro S, et al. Human beta-tryptase is a ring-like tetramer with active sites facing a central pore. Nature. 1998;392:306-311.
43. Faber JP, Poller W, Olek K, et al. The molecular basis of alpha 1-antichymotrypsin deficiency in a heterozygote with liver and lung disease. J Hepatol. 1993;18:313-321.
44. Lindmark B, Wallengren J. Heterozygous alpha 1-antichymotrypsin deficiency may be associated with cold urticaria. Allergy. 1992;47:456-458.
45. Reilly CF, Tewksbury DA, Schechter NM, Travis J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem. 1982;257:8619-8622.
46. Wintroub BU, Schechter NB, Lazarus GS, Kaempfer CE, Schwartz LB. Angiotensin I conversion by human and rat chymotryptic proteinases. J Invest Dermatol. 1984;83:336-339.
47. Longley BJ, Tyrrell L, Ma Y, et al. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci USA. 1997;94:9017-9021.
48. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med. 1991;174:821-825.
49. Nakano A, Kishi F, Minami K, et al. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol. 1997;159:1987-1992.
50. Baddeley SM, Bacon AS, McGill JI, et al. Mast cell distribution and neutral protease expression in acute and chronic allergic conjunctivitis. Clin Exp Allergy. 1995;25:41-50.
51. E. Eden, D. Mitchell, B. Mehlman, et al. Atopy, asthma and emphysema in patients with severe alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 1997;156:68-74.
52. von Ehrenstein OS, Maier EM, Weiland SK, et al. Alpha1 antitrypsin and the prevalence and severity of asthma. Arch Dis Child. 2004;89:230-231.